Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review

Chirgwin, Jacquie; Chua, S.L.

doi:10.1016/j.breast.2011.06.004

Cited by 16 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous global phase III study observed that weekly administration of nab-paclitaxel plus carboplatin yielded a significantly higher overall response rate compared with solvent-based paclitaxel plus carboplatin in patients with non-small cell lung cancer (NSCLC) (8). Nab-paclitaxel, a 130-nm albumin-bound paclitaxel formulation, is a promising novel agent for the treatment of NSCLC, and breast and gastric cancer (9,10). A previous preclinical study reported that nab-paclitaxel exhibited greater antitumor activity than equitoxic doses of Cremophor-based paclitaxel in xenograft models of lung (H522), breast (MX-1), ovarian (SK-OV-3), prostate (PC-3) and colon (HT29) human tumors (11).…”

Section: Discussionmentioning

confidence: 99%

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

et al. 2015

View full text Add to dashboard Cite

Abstract. Thymic large cell neuroendocrine carcinomas (LCNECs) are rare, and the optimal regimen for second and subsequent lines of chemotherapy for the treatment of LCNECs remains unknown. In the present case study, a 59-year-old male with post-operative recurrent thymic LCNEC was treated with nab-paclitaxel and carboplatin every 4 weeks as third-line chemotherapy, and a partial response was achieved following 4 cycles of this regimen. The patient developed grade 4 neutropenia and grade 3 leukopenia, but none of the other toxicities, including peripheral neuropathy, were severe. Therefore, the patient was able to tolerate this salvage chemotherapy. To the best of our knowledge, the present study is the first case demonstrating clinically meaningful antitumor activity by combination chemotherapy with carboplatin and nab-paclitaxel, resulting in a positive response in a patient with thymic LCNEC.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Many other Phase II neoadjuvant studies evaluating regimens including nab-PTX among HER2-negative patients have shown a wide range of pCR rates, from 7% to 25% (17)(18)(19) C, 500 mg/m 2 Day 1) in locally advanced breast cancer and reported a pCR rate of 17% in HER2-negative patients. We considered several reasons for the disappointingly low rate of pCR in the current study.…”

Section: Discussionmentioning

confidence: 99%

“…Some investigations have displayed a favorable pCR rate of 20-50% in HER2-negative patients who received qw nab-PTX in combination with carboplatin and bevacizumab in a neoadjuvant setting (17,23,24). Thus, the majority of neoadjuvant studies with nab-PTX have demonstrated satisfactory efficacy in combination regimes, but have not compared it with solvent-based taxanes (19). On the other hand, the radiological response after initiation of nab-PTX monotherapy in the current study demonstrated an acceptably high ORR of 71%, comparable to that of 60-70% reported in previous neoadjuvant studies on docetaxel and anthracycline (25)(26)(27) (Fig.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety

Shimada

Ueda

Sendo

et al. 2015

Japanese Journal of Clinical Oncology

View full text Add to dashboard Cite

Objective: Nanoparticle albumin-bound paclitaxel (nab-PTX) is a solvent-free paclitaxel coupled to human albumin without an associated increase in toxicity. The neoadjuvant study of primary breast cancer was planned to evaluate tumor response and safety of triweekly nanoparticle albumin-bound paclitaxel. Methods: Patients with Stage II/III HER2-negative primary breast cancer received four courses of nanoparticle albumin-bound paclitaxel 260 mg/m 2 every 3 weeks (q3w), followed by four courses of epirubicin 90 mg/m 2 plus cyclophosphamide 600 mg/m 2 q3w. Tumor response after nanoparticle albumin-bound paclitaxel was histologically evaluated. In addition, the clinical response, breastconserving rate and safety of this treatment were monitored. Results: Among 53 patients who received nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide neoadjuvant chemotherapy, pathological complete response and near-pathological complete response were confirmed in 3 (5.7%) and 7 (13.2%) patients who had surgery, respectively. The overall objective response rate was 71.7% after completion of chemotherapy. Based on Positron Emission Tomography Response Criteria in Solid Tumors using 18 F-fluorodeoxyglucose, complete metabolic response and partial metabolic response after 2-3 courses of nanoparticle albumin-bound paclitaxel were 15.1 and 52.8%, respectively. The most common significant toxicities of q3w nanoparticle albumin-bound paclitaxel were Grade 3 muscle pain, neuropathy and febrile neutropenia, each in 1 (1.9%) patient. There were no incidences of anaphylaxis or Grade 4/5 adverse events. Conclusion: Neoadjuvant chemotherapy using q3w nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide was feasible in breast cancer patients with acceptable clinical response and drug tolerance, but conferred a low rate of pathological complete response. Monotherapy with q3w nanoparticle albumin-bound paclitaxel could be an appropriate substitute for solvent-based taxane in terms of therapeutic and safety management.

show abstract

“…paclitaxel, and exhibit greater neurologic and hematologic toxicity. [47, 48] However, improving tumor specific targeting, optimizing the size and shape of nanoparticle and optimizing the tumor specificity of the gatekeeper may overcome these obstacles. [49, 50] Further, by exploiting tumor surface-specific features, an active targeting strategy can be developed which in turn enables the specific targeting of malignant cells.…”

Section: Inroductionmentioning

confidence: 99%

Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle

et al. 2018

View full text Add to dashboard Cite

At the intersection of the newly emerging fields of optoacoustic imaging and theranostic nanomedicine, promising clinical progress can be made in dismal prognosis of ovarian cancer. An acidic pH targeted wormhole mesoporous silica nanoparticle (V7-RUBY) was developed to serve as a novel tumor specific theranostic nanoparticle detectable using multispectral optoacoustic tomographic (MSOT) imaging. We report the synthesis of a small, < 40 nm, biocompatible asymmetric wormhole pore mesoporous silica core particle that has both large loading capacity and favorable release kinetics combined with tumor-specific targeting and gatekeeping. V7-RUBY exploits the acidic tumor microenvironment for tumor-specific targeting and tumor-specific release. In vitro, treatment with V7-RUBY containing either paclitaxel or carboplatin resulted in increased cell death at pH 6.6 in comparison to drug alone (p < 0.0001). In orthotopic ovarian xenograft mouse models, V7-RUBY containing IR780 was specifically detected within the tumor 7X and 4X higher than the liver and >10X higher than in the kidney using both multispectral optoacoustic tomography (MSOT) imaging with secondary confirmation using near infrared fluorescence imaging (p < 0.0004). The V7-RUBY system carrying a cargo of either contrast agent or an anti-neoplastic drug has the potential to become a theranostic nanoparticle which can improve both diagnosis and treatment of ovarian cancer.

show abstract

Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: A clinical review

Cited by 16 publications

References 55 publications

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Successful chemotherapy with carboplatin and nab-paclitaxel for thymic large cell neuroendocrine carcinoma: A case report

Neoadjuvant triweekly nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for Stage II/III HER2-negative breast cancer: evaluation of efficacy and safety

Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle

Contact Info

Product

Resources

About